biotech
biotech Articles
Over the past week, a few biotech companies made absolutely massive runs, while others fell off a cliff. Here are a few of the standouts from the past week.
Published:
Last Updated:
Menlo Therapeutics expects to price more than 5 million shares in the range that results in an initial public offering valued up to more than $104 million.
Published:
Last Updated:
The December 29 short interest data have been compared with the previous report, and short interest in the selected biotech stocks was mixed.
Published:
Last Updated:
Alder Biopharmaceuticals saw its shares make a solid gain on Monday amid a blizzard of updates from the company.
Published:
Last Updated:
Axovant Sciences watched its shares practically get halved in Monday’s session after the firm provided an update from a few of its midstage clinical trials.
Published:
Last Updated:
Credit Suisse has put together a list of biopharma companies in its coverage universe that stand to make significant moves in 2018.
Published:
Last Updated:
While most secondary offerings would bring down the price of the stock, this case is different and shareholders are cheering this dilution because it might bring about something greater.
Published:
Last Updated:
Merrill Lynch believes that this could be the year biotechs break out. The firm has a few picks, bad and good, that it believes will play a big role in the coming year.
Published:
Last Updated:
Audentes Therapeutics shares made a handy gain on Thursday after the company announced positive interim data for a midstage trial.
Published:
Last Updated:
24/7 Wall St. screened the Stifel specialty pharmaceutical list and found five stock rated Buy that have massive upside potential and probably don’t have the investment risk of some of the more...
Published:
Last Updated:
Sangamo Therapeutics shares made a handy gain on hump day after the firm announced that it would be collaborating with pharma giant Pfizer.
Published:
Last Updated:
Trevena saw its shares make a handy gain to start out Wednesday after the firm announced that the FDA accepted its most recent NDA for Olinvo.
Published:
Last Updated:
We screened our 24/7 Wall St. research database for hot biotech ideas and found four companies that are offering big upside for aggressive accounts. All are rated Buy and have the potential to...
Published:
Last Updated:
There can be some big biotech winners in 2018, given the changing landscape, and any of these 12 could be one.
Published:
Last Updated:
Jefferies has compiled a list of over 30 biotech events taking place in 2018 that could result in significant stock moves. Some stocks have the potential to double or even crater, should a study be...
Published:
Last Updated: